The Rs 541-crore Cipla has introduced its indigenously developed anti-AIDS drug, lamivudine, in both the domestic and overseas market at less than half the prevailing global prices. Cipla's early entry is significant given that original patent holder Glaxo is yet to hit the Indian market with its lamivudine brand.